Inhibition of hERG Channel Trafficking: An Under-Explored Mechanism for Drug-Induced QT Prolongation-Reference-Cited by-同舟云学术

Inhibition of hERG Channel Trafficking: An Under-Explored Mechanism for Drug-Induced QT Prolongation

Published:2008-10-20 Issue:10 Volume:3 Page:1501-1502
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Yeung Kap-Sun,Meanwell Nicholas A.

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Reference20 articles.

1. hERG potassium channels and cardiac arrhythmia

2. The impact of drug-induced QT interval prolongation on drug discovery and development

3. hERG Channel Physiology and Drug‐Binding Structure–Activity Relationships

4. Heat shock protein 90 (Hsp90) inhibitor geldanamycin and arsenic trioxide have both been shown to inhibit hERG trafficking by inhibiting the formation of the hERG-Hsp90 complex;

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational insights into the mechanisms underlying structural destabilization and recovery in trafficking-deficient hERG mutants;Frontiers in Molecular Biosciences;2024-08-13

2. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study;Pharmacology Research & Perspectives;2023-02

3. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review;Expert Opinion on Drug Safety;2018-09-17

4. Computational Multi-Target Drug Design;Methods in Pharmacology and Toxicology;2018

5. Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies;Clinical Drug Investigation;2016-09-14